Search results for "blood coagulation tests"

showing 10 items of 27 documents

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolong…

2014

Pharmacokinetic properties of recombinant FVIIa in inherited FVII deficiency account for a large volume of distribution at steady state and a prolonged pharmacodynamic effect -

HeredityPharmacokinetic inherited Factor VII deficiencyFactor VII DeficiencySocio-culturaleFactor VIIaPharmacologySeverity of Illness IndexPharmacokineticsPredictive Value of Testshemic and lymphatic diseasesHumansMedicineGenetic Predisposition to DiseaseFVII deficiencyRegistriescardiovascular diseasesBlood CoagulationVolume of distributionbiologyCoagulantsbusiness.industryVascular biologyrFVIIaHematologyFactor VIIRecombinant ProteinsPhenotypeTreatment OutcomerFVIIa; FVII deficiency; pharmacokineticsRecombinant factor VIIaPharmacodynamicsbiology.proteinBlood Coagulation TestsSteady state (chemistry)Drug Monitoringbusinesspharmacokinetics
researchProduct

Thromboelastographic profiles as a tool for thrombotic risk in digestive tract cancer

2007

Background: Quantification of the magnitude of thrombotic risk associated with malignancy and with anti-cancer therapy is indispensable to use anticoagulant drugs which selectively interfere with haemostatic mechanisms protecting patients from venous thromboembolism (VTE) and probably from tumor progression. However, none of activation coagulation markers has any predictive value for the occurrence of the thrombotic events in one individual patient. Current clotting methods can’t reveal the overall dynamic clot formation; in contrast thromboelastographic methods specifically assess overall coagulation kinetics and its strength in whole blood. Aim: Objective of study was to evaluate if the a…

KineticMaleOriginal contributionsRisk FactorCarcinomaSex FactorBlood Coagulation TestMiddle AgedThrombelastographyKineticsSex FactorsReference ValuesRisk FactorsStomach NeoplasmsStomach NeoplasmCase-Control StudiesArea Under CurveThromboembolismHumansFemaleReference ValueBlood Coagulation TestsCase-Control StudieAgedHuman
researchProduct

Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference.

2016

Abstract Patients with cirrhosis present with hemostatic alterations secondary to reduced availability of pro-coagulant and anti-coagulant factors. The net effect of these changes is a rebalanced hemostatic system. The Italian Association of the Study of the Liver (AISF) and the Italian Society of Internal Medicine (SIMI) promoted a consensus conference on the hemostatic balance in patients with cirrhosis. The consensus process started with the review of the literature by a scientific board of experts and ended with a formal consensus meeting in Rome in December 2014. The statements were graded according to quality of evidence and strength of recommendations, and approved by an independent …

Liver CirrhosisCirrhosisBleeding; Cirrhosis; Hemostasis; Thrombosis; Hepatology; GastroenterologySettore MED/09 - Medicina InternaBleeding; Cirrhosis; Hemostasis; Thrombosis; Anticoagulants; Coagulants; Drug Monitoring; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Cirrhosis; Postoperative Hemorrhage; Thrombosis; Blood Coagulation Tests; Hemostasis; Hepatology; Gastroenterology0302 clinical medicineEsophageal and Gastric VariceBlood coagulation testConsensus conferenceGastroenterologyThrombosisOptimal managementCirrhosisCoagulant030220 oncology & carcinogenesisThrombosi030211 gastroenterology & hepatologyBlood Coagulation TestsDrug MonitoringGastrointestinal HemorrhageHumanmedicine.medical_specialtyLiver CirrhosiBleeding; Cirrhosis; Hemostasis; Thrombosis; Gastroenterology; HepatologyPostoperative HemorrhageEsophageal and Gastric VaricesNO03 medical and health sciencesInternal medicinemedicineHumansIn patientIntensive care medicineHemostasisCirrhosiHepatologybusiness.industryCoagulantsBleeding; Cirrhosis; Hemostasis; ThrombosisBleedingAnticoagulantAnticoagulantsThrombosisHepatologyHemostasiBlood Coagulation Testmedicine.diseaseSurgeryHemostasisbusinessDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

The prescription of direct oral anticoagulants in the elderly: An observational study of 19 798 Ambulatory subjects.

2020

International audience; Objective Direct oral anticoagulants (DOACs) are increasingly prescribed to elderly people, but the epidemiologic data for this population remains scarce. We compared the elderly population taking DOACs and those not taking DOACs (noDOAC). Method We included individuals over 75 years old, affiliated to Mutualite Sociale Agricole of Burgundy (a French regional health insurance agency), who had been refunded for a prescribed DOAC between 1st and 30th September 2017. The DAOC group (DAOCG) and noDOAC group (noDOACG) were compared in terms of demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs. In the DOACG, we compared the…

MaleAdministration Oral030204 cardiovascular system & hematologyKidney Function Tests0302 clinical medicineRivaroxabanMedicineDisease030212 general & internal medicineProspective StudiesPractice Patterns Physicians'Aged 80 and overeducation.field_of_studyFrailtyVenous ThromboembolismGeneral MedicineMetaanalysisManagement3. Good healthDabigatranHealthCreatinineAmbulatoryPlatelet aggregation inhibitorApixabanFemaleBlood Coagulation TestsFranceSafetymedicine.drugmedicine.medical_specialtyPyridonesPopulationDrug PrescriptionsDabigatran03 medical and health sciencesInternal medicineHumansMedical prescriptioneducationAntihypertensive AgentsAgedRivaroxabanbusiness.industryWarfarinAnticoagulantsBlood Cell CountAtrial-FibrillationChronic DiseasePyrazolesWarfarinbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPlatelet Aggregation InhibitorsInternational journal of clinical practiceREFERENCES
researchProduct

Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit …

2003

SummaryThe aim of the present study was to investigate the efficacy of three different parenterally administered anticoagulants for the prevention of thrombus formation on artificial heart valves in an experimental rabbit model.Unfractionated heparin was administered intravenously in group I (n = 10), Enoxaparin subcutaneously in group II (n = 10), fondaparinux intravenously in group III (n = 10), and no medication was administered to group IV (n = 9). Leaflets from Sulzer Carbomedics bileaflet mechanical heart valves were placed in a flow chamber. The flow chamber was filled with blood in a continuous circulation between the carotid artery and the jugular vein.In group IV the flow chamber …

MaleArtificial heart valvemedicine.drug_classmedicine.disease_causeFondaparinuxPolysaccharidesmedicineAnimalsHeart valveEnoxaparinThrombusHeparinbusiness.industryAnticoagulantAnticoagulantsThrombosisHematologyHeparinmedicine.diseaseFondaparinux SodiumMicroscopy Electronmedicine.anatomical_structureFondaparinuxHeart Valve ProsthesisAnesthesiaBlood Coagulation TestsRabbitsbusinessEnoxaparin sodiummedicine.drugThrombosis and Haemostasis
researchProduct

A novel two base pair deletion in the factor V gene associated with severe factor V deficiency

2001

We studied a family in which the proband, a 13-year-old boy, had unmeasurable plasma levels of coagulation factor V antigen and activity. Clinical symptoms were severe, with several episodes of haemorrhages in the mucosal tracts (gastrointestinal, nose and urinary) and recurrent haemarthroses that caused permanent arthropathy. Sequence analysis of the factor V gene demonstrated the presence of a novel 2 base pair (bp) homozygous deletion in exon 13 at positions 2833-2834. This mutation, present in the heterozygous state in the asymptomatic mother and absent in the healthy brother, introduced a frameshift and a premature stop at codon 900. This would predict the synthesis of a truncated fact…

MaleProbandFactor V DeficiencyAdolescentMutantBiologymedicine.disease_causeFrameshift mutationExonmedicineHumansRNA MessengerBase PairingGeneGeneticsMutationReverse Transcriptase Polymerase Chain ReactionHomozygoteFactor VFactor VSequence Analysis DNAHematologyMolecular biologybiology.proteinBlood Coagulation TestsFactor V DeficiencyGene DeletionBritish Journal of Haematology
researchProduct

Stereoselective drug distribution and anticoagulant potency of the enantiomers of phenprocoumon in rats

1977

Abstract The elimination, distribution and anticoagulant activity of S(—)-, R(+)-, and R,S(±)-phenprocoumon were determined in male Wistar-Lewis rats after intravenous injection of a single dose of 0·6 mg kg−1. From the plasma concentrations which elicited the same anticoagulant effect, S(—)-phenprocoumon was 4 to 5 times more potent than R(+)-phenprocoumon. The potency of the racemate was between those of the enantiomers. The mean biologic half-life of the S(—)-enantiomer was shorter (12·5 h) than that of R(+)-phenprocoumon (17·8 h). No differences were observed in the apparent volume of distribution. However, the mean liver: plasma concentration ratio was higher for the S(—)-(6·9) than fo…

MaleTime Factorsmedicine.drug_classPharmaceutical ScienceIn Vitro TechniquesPharmacologyPhenprocoumonPharmacokineticsmedicineAnimalsPotencyDistribution (pharmacology)PharmacologyVolume of distributionChemistryAnticoagulantAnticoagulantsRats Inbred StrainsStereoisomerism4-HydroxycoumarinsBlood ProteinsRatsKineticsLiverPhenprocoumonStereoselectivityBlood Coagulation TestsEnantiomerProtein Bindingmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

Coagulation abnormalities in lacunar and cortical ischemic stroke are quite different

1998

In order to clarify the coagulation profile accompanying ischemic stroke, which may have implications on therapeutic strategies, we performed a prospective study to evaluate the hemostatic parameters in the first 24 h after the onset of cortical atherothrombotic infarct and lacunar infarction. Twenty-seven patients with cortical atherothrombotic infarction and 27 patients with lacunar infarction, diagnosed on clinical and CT-scan criteria, had blood samples taken within the first 24 h after onset of the stroke, and before anticoagulant treatment had been started. Levels of fibrinogen, von Willebrand factor, D-dimers, prothrombin factors 1 + 2, anti-thrombin III, and C-protein and S-proteins…

Malemedicine.medical_specialtyFibrinogenBrain IschemiaVon Willebrand factorInternal medicinemedicineHumansProspective Studiescardiovascular diseasesProspective cohort studyStrokeAgedBlood coagulation testAged 80 and overHemostasisLupus anticoagulantbiologybusiness.industryThrombosisCerebral InfarctionGeneral MedicineMiddle Agedmedicine.diseaseCerebrovascular DisordersDementia Multi-InfarctNeurologyCoagulationHemostasisbiology.proteinCardiologyFemaleBlood Coagulation TestsNeurology (clinical)businessmedicine.drugNeurological Research
researchProduct

Anticoagulation with argatroban for elective percutaneous coronary intervention: population pharmacokinetics and pharmacokinetic-pharmacodynamic rela…

2010

The synthetic direct thrombin inhibitor argatroban has a rapid onset and offset of anticoagulation. However, there are no data about the pharmacokinetic-pharmacodynamic (PK-PD) relationship of argatroban in patients undergoing contemporary percutaneous coronary intervention (PCI) and no data about other coagulation parameters than activated clotting time (ACT) in this setting. In the ARG-E04-trial, 140 patients were randomly assigned to argatroban (250, 300, or 350 μg/kg as bolus before PCI, followed by 15, 20, or 25 μg/kg/min infusion) or unfractionated heparin (70-100 IU/kg bolus). A 2-compartment model with first-order elimination adequately described the pharmacokinetic profile of argat…

Malemedicine.medical_treatmentActivated clotting timeArginineArgatrobanAntithrombinsBolus (medicine)PharmacokineticsmedicineHumansPharmacology (medical)Blood CoagulationAgedPharmacologySulfonamidesModels Statisticalmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryHeparinEndovascular ProceduresPercutaneous coronary interventionHeparinMiddle AgedClotting timeDirect thrombin inhibitorAnesthesiaPipecolic AcidsFemaleBlood Coagulation Testsbusinessmedicine.drugJournal of clinical pharmacology
researchProduct

Current practice in managing patients on anticoagulants and/or antiplatelet agents around the time of gastrointestinal endoscopy -- a nation-wide sur…

2004

Anticoagulants and antiplatelet agents are widely used in the prophylaxis and management of thromboembolic and cardiovascular diseases. Gastrointestinal bleeding is a well-known complication of these agents. Modification of anticoagulant and antiplatelet therapy is often required in patients undergoing surgical procedures and specific recommendations for the perioperative period have been issued. Fewer data exist with regard to the use of these agents around the time of endoscopic procedures. A survey of the American Society for Gastrointestinal Endoscopy (ASGE), performed several years ago, showed a wide variation between endoscopists in the management of anticoagulants and antiplatelet ag…

Riskmedicine.medical_specialtyGastrointestinal bleedingmedicine.drug_classMEDLINEEndoscopy GastrointestinalGermanySurveys and QuestionnairesMedicineHumansIntensive care medicineBlood coagulation testmedicine.diagnostic_testbusiness.industryAnticoagulantGastroenterologyWarfarinAnticoagulantsPerioperativemedicine.diseaseSurgeryEndoscopyBlood Coagulation TestsGuideline AdherencebusinessComplicationGastrointestinal HemorrhagePlatelet Aggregation Inhibitorsmedicine.drugZeitschrift fur Gastroenterologie
researchProduct